Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung

Inclusion Criteria:

• Previously untreated, histological documented stage IIIB (not amenable for radicalregional therapy) or stage IV squamous cell carcinoma of lung. At least one measurablelesion as defined by RECIST criteria.

• At least 18 years of age.

• ECOG PS 0~1

• Patients have no previously malignant tumor history except cured cervical carcinoma insitu, basal cell carcinoma or superficial bladder cancer. Patients are also eligibleif they have received a chemotherapy regimen as neoadjuvant or adjuvant chemotherapyand the disease recurred over 12 months since the finishing of neoadjuvant or adjuvantchemotherapy.

• neutrophil ≥ 1.5 x 109 /L, Hemoglobin > 90 g/L, Platelet count > 100x109/L.

• Total bilirubin ≤ 1.5 x upper limit of normal. ALT and AST < 2.5 x upper limit ofnormal without liver metastasis, ALT and AST < 5 x upper limit of normal with livermetastasis. Serum creatinine < 1.5 x upper limit of normal.

• Urine pregnancy test is negative for woman.

• Estimated life expectancy is at least 3 months.

• Patient comply with the clinical trial protocal.

• Informed consent must be signed.

Exclusion Criteria:

• Patients who are currently undergoing other anti-tumor therapy.

• Patients who was enrolled in any other clinical trial within 4 weeks of study entry.

• Any physical examination finding, or clinical laboratory finding giving reasonablesuspicion of a disease or condition that contraindicates the use of any studymedication or render the subject at high risk from treatment.

• Central nervous system (CNS) tumor or metastatic tumor.

• Serious mental disorder.

• Serious dysgnosia.

• Other serious comorbidity.

• Alcohol or drug dependence.

• Previously allergic to drugs used in the study.